D-0421-2026 Class II Ongoing
FDA drug recall D-0421-2026 was initiated by Appco Pharma LLC on Mar 27, 2026 and is designated Class II. Reason for recall: cGMP deviation: detection of Nitrosamine Drug Substance-Related Impurities, N-nitroso-prazosin impurity C (NNP) above acceptable limits. The recall status is ongoing. Affected quantity: 28,157 bottles- 100's count.
Recall details
- Product Type
- Drugs
- Report Date
- Apr 8, 2026
- Initiation Date
- Mar 27, 2026
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 28,157 bottles- 100's count
Product description
Prazosin Hydrochloride Capsules, USP, 5mg, 100-count bottle, Rx Only, Manufactured for: Biocon Pharma Inc., Iselin, NJ, Manufactured by: Appco Pharma LLC, Piscataway, NJ, NDC 70377-068-11.
Reason for recall
cGMP deviation: detection of Nitrosamine Drug Substance-Related Impurities, N-nitroso-prazosin impurity C (NNP) above acceptable limits.
Distribution pattern
U.S.A. Nationwide
Code information
Lot:2406255UC, Exp.: 2026/MAY; 2406256UC, Exp.: 2026/JUL; 2407313UC Exp.: 2026/JUL; 2408351UC, Exp.: 2026/JUL; 2408352UC , Exp.: 2026/JUL; 2509311UC, Exp.: 2027/SEP. .
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0421-2026
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026